Skip to main content

EDITORIAL article

Front. Allergy
Sec. Therapies and Therapeutic Targets
Volume 5 - 2024 | doi: 10.3389/falgy.2024.1440549
This article is part of the Research Topic Biological Therapy for Allergic Diseases: Peculiarities, Prospects and Challenges View all 7 articles

Editorial: Biological Therapy for Allergic Diseases: Peculiarities, Prospects, and Challenges

Provisionally accepted
Ervin Mingomataj Ervin Mingomataj 1Tayseer Ibrahim Tayseer Ibrahim 2Syed A. Rizvi. Syed A. Rizvi. 3*
  • 1 Other, Tirana, Albania
  • 2 Hamad Medical Corporation, Doha, Qatar
  • 3 Larkin University, Miami, United States

The final, formatted version of the article will be published soon.

    Keywords: allergic diseases, COVID-19 -, genome-wide association studies, panitumumab), monoclonal antibodies (immunology), Targeted & personalized therapy

    Received: 29 May 2024; Accepted: 21 Jun 2024.

    Copyright: © 2024 Mingomataj, Ibrahim and Rizvi.. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Syed A. Rizvi., Larkin University, Miami, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.